HC Wainwright Forecasts Genmab A/S FY2024 Earnings

Genmab A/S (NASDAQ:GMAB) – Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Genmab A/S in a report released on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju expects that the company will earn $1.21 per share for the year. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.35 EPS.

GMAB has been the subject of a number of other research reports. BMO Capital Markets restated an “outperform” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, Redburn Atlantic started coverage on Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Stock Performance

GMAB opened at $20.80 on Monday. The firm’s fifty day moving average is $21.08 and its two-hundred day moving average is $23.91. The firm has a market cap of $13.76 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. Genmab A/S has a twelve month low of $19.85 and a twelve month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same quarter in the prior year, the business earned $0.47 earnings per share.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. bought a new stake in shares of Genmab A/S in the second quarter valued at about $457,000. Sanctuary Advisors LLC acquired a new stake in Genmab A/S in the 2nd quarter valued at approximately $1,354,000. Ritholtz Wealth Management bought a new stake in Genmab A/S in the 3rd quarter valued at approximately $314,000. Creative Planning boosted its position in Genmab A/S by 136.3% during the 3rd quarter. Creative Planning now owns 47,422 shares of the company’s stock worth $1,156,000 after acquiring an additional 27,353 shares during the last quarter. Finally, Bleakley Financial Group LLC grew its stake in shares of Genmab A/S by 7.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 30,732 shares of the company’s stock worth $749,000 after acquiring an additional 2,196 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.